China Cooperative Research Group on Qinghaosu and Its Derivatives as Antimalarials (1982). Clinical studies on the treatment of malaria with qinghaosu and its derivatives. J Tradit Chin Med 2:45–50.
China Cooperative Research Group on Qinghaosu and Its Derivatives as Antimalarials (1982) Studies on the toxicity of qinghaosu and its derivatives. J. Tradit. Chin. Med. 2:31–38.
China Cooperative Research Group on Qinghaosu and Its Derivatives as Antimalarials (1982) Chemical studies on qinghaosu (artemisinine). J. Tradit. Chin. Med. 2:3–8.
China Cooperative Research Group on Qinghaosu and Its Derivatives as Antimalarials (1982) Antimalarial efficacy and mode of action of qinghaosu and its derivatives in experimental models. J. Tradit. Chin. Med. 2:17–24.
China Cooperative Research Group on Qinghaosu and Its Derivatives as Antimalarials (1982) The chemistry and synthesis of qinghaosu derivatives. J. Tradit. Chin. Med. 2:9–16.
Meshnick, S.R., 1998. From quinine to qinghaosu: historical perspectives. In: Sherman, I.W. (Ed.). Malaria: Parasite Biology, Pathogenesis, Protection, ASM Press, Washington, DC, pp. 341–53.
Meshnick, S.R., Dobson, M.J., 2001. The history of antimalarial drugs. Antimalarial chemotherapy. In: Rosenthal, P.J. (Ed.). Mechanisms of Action, Modes of Resistance, and New Directions in Drug Development, Humana Press, Totowa, NJ, pp. 15–25.
吴毓林 (2009) 青蒿素——历史和现实的启示.化学进展 21:2365-2371
Eckstein-Ludwig U, Webb RJ, van Goethem IDA, East JM, Lee AG, Kimura M, O’Neill PM, Bray PG, Ward SA & S. Krishna S (2003) Artemisinins target the SERCA of Plasmodium falciparum. Nature 424:957-961.
Bernard J, Weil M, Boiron M, Jacquillat C, Flandrin G, and Gemon M-F (1973). Acute promyelocytic leukemia: results of treatment by daunorubicin. Blood 41:489-496.
Koeffler HP (1983). Induction of differentiation of human acute myelogenous leukemia cells: Therapeutic implications. Blood 62:709-721.
Flynn P. Miller W, Weisdorf D, Arthur D, Banning R, Branda R (1983). Retinoic acid treatment ofacute promyelocytic leukemia: In vitro and in vivo observations. Blood 62:1211-1217.
Nilsson B (1984) Probable in vivo induction of differentiation by retinoic acid acid of promyelocytes in acute promyelocytic leukemia. Br J Haematol 57:365-371.
Daenen 5, Vellenga E, van Dobbenbugh OA, Halie MR (1986). Retinoic acid as antileukemic therapy in a patient with acute promyelocytic leukemia and Aspergillus pneumonia. Blood 67:559-561.
Fontana JA, Roger iS, Durham JP (1986). The role of 13-cis retinoic acid in the remission induction of a patient with acute promyelocytic leukemia. Cancer 57:209-217.
Huang ME, Ye YC, Chen SR, Zhao JC, Gu LJ, Cai JR, Zhao L, Xie JX, Shen ZX & Wang ZY (1987). All-trans retinoic acid with or without low dose cytosine arabinoside in acute promyelocytic leukemia: report of 6 cases. Chin Med J 100:949-953.
Huang ME, Ye YC, Chen SR, Chai JR, Lu JX, Zhoa L, Gu LJ & Wang ZY (1988). Use of alltrans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72:567-572.
Huang SL, Guo AX, Xiang Y, Wang XB, HJ Ling, L Fu (1995). Clinical study on the treatment of APL mainly with composite Indigo Naturalis tablets. Chin J Hematol 16:26.
Zhang P, Wang SY, Hu LH, Shi FD, Qiu FQ, Hong LJ, Han XY, Yang HF, Song YZ, Liu YP, Zhou J, Jin ZJ (1996) Treatment of 72 cases of acute promyelocytic leukemia with intravenous arsenic trioxide. Chin. J. Hematol. 17:58–62.
Chen GQ, Zhu J, Shi XG, Ni JH, Zhong HJ, Si GY, Jin XL, Tang W, Li XS, Xong SM, Shen ZX, Sun GL, Ma J, Zhang P, Zhang TD, Gazin, Naoe T, Chen SJ, Wang Zy & Chen Z (1996). In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia. As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR α/PML proteins. Blood 88:1052–1061.
Mervis J (1996). Cancer research: ancient remedy performs new tricks. Science 273:578-
Chen GQ, Shi XG, Tang W, Xiong SM, Zhu J, Cai X, Han ZG, Ni JH, Shi GY, Jia PM, Liu MM, He KL, Niu C, Ma J, Zhang P, Zhang TD, Paul P, Naeo T, Kitamura K, Miller W, Waxman, Wang ZY, de The H, Chen SJ & Chen Z (1997). Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL), I: As2O3 exerts dose-dependent dual effects on APL cells. Blood 89:3345-3353
Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY, Zhu J, Tang W, Sun GL, Yang KQ, Chen Y, Zhou L, Fang ZW, Wang YT, Ma J, Zhang P, Zhang TD, Chen SJ, Chen Z, and Wang ZY (1997). Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL), II: clinical efficacy and pharmacokinetics in relapsed patients. Blood 89:3354-3360.
Soignet SL Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti L, Corso, D, DeBalsio A, Gabrilove J, Scheinberg DA, Pandolfi PP, Warrell RP (1998) Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N. Engl. J. Med. 339:1341–1348.
Zhang TD (1999). Studies on treatment of leukemia with traditional chinese drugs containing arsenic. On treatment of leukemia with Ailing No.1. Chinese Journal of Integrative Medicine 5:89-94.
Niu C, Yan H, Yu T, Sun HP, Liu JX, Li XS, Wu W, Zhang FQ, Chen Y, Zhou L, Li JM, Zeng XY, Ou Yang RR, Yuan MM, Ren MY, Gu FY, Cao Q, Gu BW, Su XY, Chen GQ, Xiong SM, Zhang TD, Waxman S. Wang ZY, Chen Z, Hu J, Shen ZX, Chen SJ (1999) Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 94:3315-3324.
Zhang TD, Chen GQ, Wang ZG, Wang ZY, Chen SJ & Chen Z (2001). Arsenic trioxide, a therapeutic agent for APL. Oncogene 20:7146-7153.
Zhu J, Chen Z, Lallemand-Breitenbach V, de The H (2001). How acute promyelocytic leukaemia revived arsenic. Nature Reviews Cancer 2:705-714.
张亭栋 (2003) 开发砒霜. 中国中西医结合杂志 23:65-66.
Wang ZY, & Chen Z (2008). Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 111: 2505-2515.